Further, several signal transduction pathways [mTOR, AKT, NF-kappaB (NF-κB), Fatty acid synthase (FASN), and insulin-like growth factor-1 receptor (IGF-1R)] are overexpressed in Peripheral T-cell lymphomas (PTCL), supporting the use of metformin as an inhibitor of mTORC2 and NF-κB in PTCL 168. Here, AKT1 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.